Mer/c-Met-IN-1 is a potent Mer/c-met dual inhibitor with IC50 values of 1 and 19 nM. Mer/c-Met-IN-1 can inhibit cancer cells proliferation, migration and induce apoptosis. Mer/c-Met-IN-1 can be used for the research of cancer, such as colon cancer.

Meglitinide is an ATP-sensitive potassium (KATP) channel inhibitor. Meglitinide exhibits IC50 values of 0.26 μM, 0.53 μM and 1.6 μM against KATP channels containing SUR1, SUR2A and SUR2B, respectively, with a Kd value of 7 μM for both SUR1 and SUR2A, and a Kd value of 8 μM for SUR2B. Meglitinide binds to the SUR1, SUR2A and SUR2B subunits with high affinity to close KATP channels, acting on a binding site shared by all SUR subtypes, and its interaction with SUR1 carrying the S1237Y mutation remains unchanged. Meglitinide is applicable to research related to type 2 diabetes.

MCULE-3064932370 is a covalent and allosteric SUMO E1 (heterodimer of Aos1 and Uba2) inhibitor with IC50 values ranging from 16.66 μM to 2.96 μM. MCULE-3064932370 inhibits SUMOylation of Uba2. MCULE-3064932370 has anti-cancer activity against breast cancer.

M2WJ332 is an inhibitor of the M2 proton channel of the influenza A virus M2S31N mutant M2. M2WJ332 potently inhibits the influenza A virus A/M2-S31N proton channel in Xenopus laevis oocytes, with an IC50 of 16 μM. M2WJ332 completely inhibits plaque formation by the influenza A virus carrying the M2S31N mutant. M2WJ332 is applicable to research related to influenza A virus infection.

LY580276 is an ATP-competitive ALK5 inhibitor with an IC50 of 175 nM. LY580276 inhibits transforming growth factor-β-induced epithelial-mesenchymal transition. LY580276 can be used for cancer research.

LY-326188 is a HIV-1 protease inhibitor, with an IC50 of 0.42 nM. LY326188 exhibits potent protection of HIV-1 infected cells.

LY164846 is an orally active cephalosporin. LY164846 is highly sensitive to Haemophilus influenzae (including Ampicillin-resistant strains) and Moraxella catarrhalis (with MIC90 ≤ 4 μg/mL). LY164846 is generally sensitive to Methicillin-resistant Staphylococcus aureus and Streptococcus (except Enterococcus) (with MIC90: 0.25 - 8 μg/mL), and moderately sensitive to anaerobic bacteria. LY164846 has MBC/MIC ratio to Haemophilus influenzae of ≤ 2, showing bactericidal activity. LY164846 can be used for research on respiratory and skin infections.

LTK-14A, a derivative of Garcinol, is a selective histone butyrylation inhibitor. LTK-14A does not affect acetylation. LTK-14A significantly inhibits the butyrylation of H4K5 and downregulated the expression of proadipogenic genes, thus culminating in abolished adipogenesis. LTK-14A can be used for the study of obesity.

LTD4 antagonist 3 (FK011 hydrochloride) is a LTD4 antagonist. LTD4 antagonist 3 has agonistic activity for PPAR-γ, with a fold-increase of 1.50 at 1 μM and 2.35 at 10 μM. LTD4 antagonist 3 can be used of development of non-steroidal anti-inflammatory drugs (NSAIDs).

LSD1-IN-41 (compound 7) is a potent and selective LSD1 inhibitor. LSD1-IN-41 can be used for diffuse intrinsic pontine glioma (DIPG) research when combined with HDAC inhibitors.

LP-911888 is an orally active ACSL5/ACSL1 inhibitor, with IC50 values of 1 nM and 3 nM against mouse and human ACSL5, and IC50 values of 2 nM and 9 nM against mouse and human ACSL1, respectively. LP-911888 inhibits intestinal triglyceride uptake; it also reduces body weight and food consumption in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway. LP-911888 can be used in studies of diet-induced obesity.

Lirexapride is a 5-HT4/Dopamine D2 receptor agonist. Lirexapride stimulants gastrointestinal motor. Lirexapride can be used for research on digestive system disorders.

Levomequitazine (Compound V0114) ((S)-Mequitazine), the levorotatory enantiomer of Mequitazine, is an orally active, inverse H4 receptor agonist (IC50s: 94 nM (hM2), 17 nM (hM3)). Levomequitazine strongly binds to human histamine H4 receptor. Levomequitazine antagonizes the activating action induced by histamine on H4 receptor. Levomequitazine induces a powerful and statistically significant anti-inflammatory effect. Levomequitazine can be used for research on inflammatory diseases.

Lenalidomide-CO-C7-NH2 is a CRBN-dependent intermediate of BET PROTAC degrader. Consisting of the E3 ubiquitin ligase ligand Lenalidomide conjugated with a PROTAC linker, Lenalidomide-CO-C7-NH2 induces the specific degradation of the oncoprotein BRD4. By depleting BRD4, Lenalidomide-CO-C7-NH2 effectively inhibits cancer cell proliferation, induces cell cycle arrest and promotes apoptosis, thereby exhibiting significant anti-tumor activity in xenograft models. Lenalidomide-CO-C7-NH2 serves as an important tool molecule for the study of acute myeloid leukemia.

LCK ligand-1 is a ligand targeting LCK, which serves as a target protein ligand for the synthesis of the PROTAC degrader SJ45566.

L-652343 is a dual cyclooxygenase/lipoxygenase inhibitor. L-652343 can inhibit the production of LTB4 in isolated human polymorphonuclear leukocytes treated with Calcimycin (IC50: 1.4 μM), but it is inactive in whole blood. L-652343 can be used in the research of inflammatory and immune diseases.

L-367773 is an orally active, selective oxytocin receptor antagonist, with Ki values of 26 nM and 61 nM for rat uterine oxytocin receptor and human uterine oxytocin receptor, respectively. L-367773 inhibits Oxytocin-stimulated uterine contractions.

KW-2170 hydrochloride is an alkylating agent and topoisomerase II inhibitor. KW-2170 hydrochloride stabilizes the topoisomerase II-DNA complex, causing DNA double-strand breaks, thereby preventing DNA replication and transcription, and ultimately leading to the death of tumor cells. KW-2170 hydrochloride exhibits potent and broad-spectrum anti-tumor activity in various mouse and human tumor models. KW-2170 hydrochloride can be used in the research of solid tumors.

KP-1212 is a nucleoside. KP-1212 exerts its antiviral effect by mutagenizing the viral genome. KP-1212 inhibits HIV growth.

KF 18259 is a 5-HT3-receptor antagonist. KF 18259 inhibits the wrap-restraint stress-induced propulsive motility of the proximal and distal colon.

JNK-IN-17 (Compound 9J) is a selective and potent JNK inhibitor with IC50 values of 0.039, 0.079 μM for JNK1 and JNK3. JNK-IN-17 can inhibit c-Jun phosphorylation with an IC50 of 0.082 μM in Streptozotocin-infuced INS-1 pancreatic islet β cells. JNK-IN-17 shows inhibition rate ≤ 33% on the four main P450 subtypes (2C9, 2D6, 3A4, 1A2) in human liver microsomes, indicating a relatively low risk of drug interactions. JNK-IN-17 can be used for researches of neurological and metabolic disease, such as Parkinson's disease.

JAX-77 is a potent root architecture modulator. JAX-77 maintains primary root length while substantially increasing lateral root numbers, thereby optimizing the plant’s overall root system. JAX-77 is the key intermediate metabolite formed from the hydrolysis of JAX-44 and can be converted to Indole-3-butyric acid (IBA). JAX-77 can be used for auxin biology and root development research.

JAK3-IN-19 (Compound 4) is a JAK3 inhibitor. JAK3-IN-19 can be used for cancer research.

JAK1/2 ligand 1 is the ligand of JAK1/2 and can be used for the synthesis of PROTACs, such as JAK1/2 Ligand-Linker Conjugates 1.

ITA-5 is a TBK1 inhibitor based on the structure of itaconic acid. can significantly inhibit the secretion of IFN-β. ITA-5 can inhibit the phosphorylation of TBK1, IRF3, and STAT1. ITA-5 can be used for research on autoimmune diseases and excessive inflammation.

ISA 27 is a small-molecule MDM2-p53 protein-protein interaction inhibitor. ISA 27 inhibits MDM2-mediated p53 ubiquitination and degradation. ISA 27 is promising for research of p53-mutant solid tumors (e.g., thyroid, breast cancer).

Im-m7GDP is the cap reagent that can be used for nucleic acid synthesis.

ICI 198615 is a lipoxygenase inhibitor. ICI 198615 inhibits the activity of lipoxygenases involved in eicosanoid metabolism. ICI 198615 attenuates the early phase of bronchoconstriction induced by ET-1.

ICI 185282 is a potent, selective, orally active thromboxane A2 (TXA₂) receptor antagonist. ICI 185282 causes dose-dependent inhibition of U-46619-induced platelet aggregation ex-vivo in guinea-pig. ICI 185,282 inhibits bronchospasm induced by U-46619, PGD2, PGF2α, arachidonic acid, LTD4 and PAF in vivo. ICI 185282 can be used for bronchial asthma research.

IAXO-101 iodide is a TLR4/CD14 blocker. IAXO-101 iodide can inhibit the innate immune pathway of CD14. IAXO-101 iodide is capable of improving the recording performance of intracortical microelectrodes in mice. IAXO-101 iodide can also partially alleviate fetal growth restriction, placental vascular damage, and reduce the level of the inflammatory factor TNF-α in pregnant mice infected with malaria. IAXO-101 iodide can be used in the research of gestational malaria and inflammatory diseases.